Skip to main content
. Author manuscript; available in PMC: 2022 Sep 7.
Published in final edited form as: Lancet Microbe. 2021 Dec 6;3(2):e113–e123. doi: 10.1016/S2666-5247(21)00235-4

Figure 4. Identification of signatures associated with rVSVΔG-ZEBOV-GP vaccination at the peak of the transcriptomic response (day 1) in a pooled dataset of the Geneva and USA cohorts.

Figure 4

The pooled dataset of the Geneva and USA cohorts was used to train the model in which 70% of each dataset was used as training set and the remaining 30% of each dataset was used as test set. (A) Receiver operating characteristic curve and AUC show the classifying performance of the trained model. (B) Predicted probability plots showing the accuracy of the identified pooled biomarker signature across timepoints in box-and-whiskers plots (5–95 percentiles) either in the pooled cohort in which train-test split was performed or in the single validation cohorts. AUC=area under the receiver operating characteristic curve. rVSVΔG-ZEBOV-GP=recombinant vesicular stomatitis virus vector expressing the Zaire Ebola virus glycoprotein.